Cover Image
Market Research Report

Orthopedic Biomaterials Market Report Suite | Australia | 2020-2026 | Medsuite

Published by iData Research Inc. Product code 925593
Published Content info 285 Pages
Delivery time: 1-2 business days
Price
Back to Top
Orthopedic Biomaterials Market Report Suite | Australia | 2020-2026 | Medsuite
Published: February 7, 2020 Content info: 285 Pages
Description

The full report suite on the Australian market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) allografts and synthetics. This report also includes orthopedic growth factors and hyaluronic acid (HA) viscosupplementation. The orthopedic biomaterials market includes bone graft substitutes, HA viscosupplementation and growth factors. In 2019, the largest segment was the orthopedic bone graft substitute market, which includes allografts, DBM allografts and synthetics. In Australia, synthetics are the most popular material for orthopedic bone graft substitute procedures, largely due to a limited supply of allografts and DBM allografts.

Table of Contents
Product Code: iDATA_AUOB20_MS

TABLE OF CONTENTS

TABLE OF CONTENTS I

LIST OF FIGURES VIII

LIST OF CHARTS XV

EXECUTIVE SUMMARY 1

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 3

MARKET TRENDS 5

MARKET DEVELOPMENTS 6

PROCEDURE NUMBERS 7

MARKETS INCLUDED 8

KEY REPORT UPDATES 10

VERSION HISTORY 10

RESEARCH METHODOLOGY 11

  • Step 1: Project Initiation & Team Selection 11
  • Step 2: Prepare Data Systems and Perform Secondary Research 14
  • Step 3: Preparation for Interviews & Questionnaire Design 16
  • Step 4: Performing Primary Research 17
  • Step 5: Research Analysis: Establishing Baseline Estimates 19
  • Step 6: Market Forecast and Analysis 20
  • Step 7: Identify Strategic Opportunities 22
  • Step 8: Final Review and Market Release 23
  • Step 9: Customer Feedback and Market Monitoring 24

PRODUCT ASSESSMENT 25

  • 2.1 INTRODUCTION 25
  • 2.2 PRODUCT PORTFOLIOS 25
    • 2.2.1 Bone Graft Substitutes 26
    • 2.2.2 Growth Factors 32
      • 2.2.2.1 Other products 35
    • 2.2.3 Hyaluronic Acid Viscosupplementation (HAV) 37
  • 2.3 REGULATORY ISSUES AND RECALLS 40
    • 2.3.1 Bone Graft Substitutes 40
      • 2.3.1.1 Allografts 40
      • 2.3.1.1.1 MTF 40
      • 2.3.1.2 DBM 40
      • 2.3.1.2.1 AlloSource 40
      • 2.3.1.2.2 SeaSpine 41
      • 2.3.1.2.3 RTI Surgical 41
      • 2.3.1.3 Synthetics 41
      • 2.3.1.3.1 Abyrx 41
      • 2.3.1.3.2 Zimmer Biomet 42
    • 2.3.2 Growth Factors 42
      • 2.3.2.1.1 Medtronic 42
    • 2.3.3 Hyaluronic Acid Viscosupplementation 43
      • 2.3.3.1 Three-injection 43
      • 2.3.3.1.1 Ferring Pharmaceuticals 43
  • 2.4 CLINICAL TRIALS 44
    • 2.4.1 Bone Graft Substitutes 44
      • 2.4.1.1 Allografts 44
      • 2.4.1.1.1 Providence Medical Technology 44
      • 2.4.1.1.2 The University of Texas Health Science 44
      • 2.4.1.1.3 University of Winchester 45
      • 2.4.1.2 BDM 45
      • 2.4.1.2.1 K2M 45
      • 2.4.1.2.2 Zimmer Biomet 46
      • 2.4.1.3 Synthetics 46
      • 2.4.1.3.1 Baxter 46
      • 2.4.1.3.2 Bonesupport 47
      • 2.4.1.3.3 DePuy Synthes 47
      • 2.4.1.3.4 NuVasive 49
      • 2.4.1.3.5 RTI surgical 49
      • 2.4.1.3.6 Sunstar GUIDOR 50
      • 2.4.1.4 Other materials and comparison 51
      • 2.4.1.4.1 Seoul National University Hospital. 51
      • 2.4.1.4.2 Sewon Cellontech 51
      • 2.4.1.4.3 SurgaColl Technologies Limited 52
      • 2.4.1.4.4 University of Colorado 52
      • 2.4.1.4.5 University of Padova 53
    • 2.4.2 Growth Factors 53
      • 2.4.2.1.1 Bioventus 53
      • 2.4.2.1.2 Cerapedics 54
      • 2.4.2.1.3 CGBio 54
      • 2.4.2.1.4 Isto 55
      • 2.4.2.1.5 Medtronic 55
      • 2.4.2.1.6 NuVasive 57
      • 2.4.2.1.7 Wright 57
      • 2.4.2.1.8 Others 58
    • 2.4.3 Hyaluronic Acid Viscosupplementation 59
      • 2.4.3.1.1 Anika Therapeutics 59
      • 2.4.3.1.2 Bioventus 60
      • 2.4.3.1.3 Cario University 61
      • 2.4.3.1.4 Ferring Pharmaceuticals 61
      • 2.4.3.1.5 Federal University of Minas Gerais 62
      • 2.4.3.1.6 Fidia Pharma USA Inc. 62
      • 2.4.3.1.7 Istituto Ortopedico Rizzoli 63
      • 2.4.3.1.8 University Hospital 63
      • 2.4.3.1.9 Universidade Nova de Lisboa 64

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 65

  • 3.1 INTRODUCTION 65
    • 3.1.1 Bone Graft Substitutes 65
    • 3.1.2 Growth Factors 65
    • 3.1.3 Hyaluronic Acid (HA) Viscosupplementation 66
  • 3.2 CURRENCY EXCHANGE RATE 67
  • 3.3 MARKET OVERVIEW AND TREND ANALYSIS 68
  • 3.4 DRIVERS AND LIMITERS 76
    • 3.4.1 Market Drivers 76
    • 3.4.2 Market Limiters 76
  • 3.5 COMPETITIVE MARKET SHARE ANALYSIS 78
  • 3.6 MERGERS AND ACQUISITIONS 84
  • 3.7 COMPANY PROFILES 86
    • 3.7.1 Anika Therapeutics 86
    • 3.7.2 Bioventus 87
    • 3.7.3 DePuy Synthes 88
    • 3.7.4 Ferring Pharmaceuticals 89
    • 3.7.5 Fidia Pharmaceuticals 90
    • 3.7.6 Genzyme (Sanofi Group) 91
    • 3.7.7 Harvest Technologies (Terumo BCT) 92
    • 3.7.8 Integra LifeSciences 93
    • 3.7.9 Medtronic 94
    • 3.7.10 Musculoskeletal Transplant Foundation (MTF) 96
    • 3.7.11 NuVasive 97
    • 3.7.12 Orthofix 98
    • 3.7.13 RTI Surgical 99
    • 3.7.14 Stryker 100
    • 3.7.15 Vericel Corporation (formerly Aastrom Bioscience) 101
    • 3.7.16 Zimmer Biomet 102
  • 3.8 SWOT ANALYSIS 104
    • 3.8.1 Anika Therapeutics 104
    • 3.8.2 Bioventus 106
    • 3.8.3 DePuy Synthes 108
    • 3.8.4 Ferring Pharmaceuticals 109
    • 3.8.5 Fidia Pharmaceuticals 110
    • 3.8.7 Harvest Technologies (Terumo BCT) 112
    • 3.8.8 Integra LifeSciences 113
    • 3.8.9 Medtronic 114
    • 3.8.10 Musculoskeletal Transplant Foundation (MTF) 115
    • 3.8.11 NuVasive 116
    • 3.8.12 Orthofix 117
    • 3.8.14 Stryker 119
    • 3.8.15 Vericel Corporation (formerly Aastrom Bioscience) 120
    • 3.8.16 Zimmer Biomet 121

PROCEDURE NUMBERS 123

  • 4.1 INTRODUCTION 123
  • 4.2 PROCEDURES 124
    • 4.2.1 Orthopedic Biomaterial Procedures by Segment 124
    • 4.2.2 Orthopedic Bone Grafting Procedures 126
      • 4.2.2.1 Units per Procedure by Indication 126
      • 4.2.2.2 Orthopedic Bone Grafting Procedures by Material 127
      • 4.2.2.2.1 Autograft Procedures by Indication 129
      • 4.2.2.2.2 Allograft Procedures by Indication 132
      • 4.2.2.2.3 DBM Allograft Procedures by Indication 135
      • 4.2.2.2.4 Synthetic Procedures by Indication 138
      • 4.2.2.3 Orthopedic Bone Grafting Procedures by Indication 141
    • 4.2.3 Orthopedic Growth Factor Procedures 144
    • 4.2.4 Hyaluronic Acid Supplementation Procedures 146
      • 4.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle 146

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET 148

  • 5.1 INTRODUCTION 148
  • 5.2 MARKET OVERVIEW 149
    • 5.2.1 Orthopedic Bone Graft Substitute Market by Material 149
    • 5.2.2 Orthopedic Bone Graft Substitute Market by Indication 154
  • 5.3 MARKET ANALYSIS AND FORECAST 160
    • 5.3.1 Total Orthopedic Bone Graft Substitute Market 160
    • 5.3.2 Orthopedic Bone Graft Substitute Market by Material 162
      • 5.3.2.1 Allograft Bone Graft Substitute Market 162
      • 5.3.2.1.1 Allograft Bone Graft Substitute Market by Indication 164
      • 5.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 178
      • 5.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 180
      • 5.3.2.3 Synthetic Bone Graft Substitute Market 194
      • 5.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication 196
    • 5.3.3 Orthopedic Bone Graft Substitute Market by Indication 210
      • 5.3.3.1 Spine Bone Graft Substitute Market 210
      • 5.3.3.2 Cervical Spine Bone Graft Substitute Market 212
      • 5.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market 214
      • 5.3.3.4 Trauma Bone Graft Substitute Market 216
      • 5.3.3.5 Non-Union Trauma Bone Graft Substitute Market 218
      • 5.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market 220
      • 5.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market 222
      • 5.3.3.8 Hip Reconstruction Bone Graft Substitute Market 224
      • 5.3.3.9 Knee Reconstruction Bone Graft Substitute Market 226
      • 5.3.3.10 Foot Reconstruction Bone Graft Substitute Market 228
      • 5.3.3.11 Craniomaxillofacial Bone Graft Substitute Market 230
      • 5.3.3.12 Oncology Bone Graft Substitute Market 232
  • 5.4 DRIVERS AND LIMITERS 234
    • 5.4.1 Market Drivers 234
    • 5.4.2 Market Limiters 234
  • 5.5 COMPETITIVE MARKET SHARE ANALYSIS 236

ORTHOPEDIC GROWTH FACTOR MARKET 240

  • 6.1 INTRODUCTION 240
    • 6.1.1 BMP-2 (Medtronic) 241
    • 6.1.2 PDGF-BB (Wright Medical) 241
    • 6.1.3 P-15 Synthetic Small Peptide (Cerapedics) 241
    • 6.1.4 P-15 Synthetic Small Peptide (Biocomposites) 241
  • 6.2 MARKET ANALYSIS AND FORECAST 242
  • 6.3 DRIVERS AND LIMITERS 244
    • 6.3.1 Market Drivers 244
    • 6.3.2 Market Limiters 244
  • 6.4 COMPETITIVE MARKET SHARE ANALYSIS 246

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET 249

  • 7.1 INTRODUCTION 249
    • 7.1.1 Benefits of Viscosupplementation 250
    • 7.1.2 Synovial Fluid 250
  • 7.2 MARKET OVERVIEW 251
  • 7.3 MARKET ANALYSIS AND FORECAST 257
    • 7.3.1 Total Hyaluronic Acid Viscosupplementation Market 257
    • 7.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 259
    • 7.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market 261
  • 7.4 DRIVERS AND LIMITERS 263
    • 7.4.1 Market Drivers 263
    • 7.4.2 Market Limiters 263
  • 7.5 COMPETITIVE MARKET SHARE ANALYSIS 265

ABBREVIATIONS 268

LIST OF CHARTS

  • Chart 1 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 2
  • Chart 1 2: Orthopedic Biomaterials Market Overview, Australia, 2019 & 2026 2
  • Chart 3 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 71
  • Chart 3 2: Orthopedic Biomaterials Market Breakdown, Australia, 2019 72
  • Chart 3 3: Orthopedic Biomaterials Market Breakdown, Australia, 2026 73
  • Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Australia, 2016 - 2026 75
  • Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, Australia, 2019 83
  • Chart 4 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 125
  • Chart 4 2: Orthopedic Bone Grafting Procedures by Material, Australia, 2016 - 2026 128
  • Chart 4 3: Autograft Procedures by Indication, Australia, 2016 - 2026 131
  • Chart 4 4: Allograft Procedures by Indication, Australia, 2016 - 2026 134
  • Chart 4 5: DBM Allograft Procedures by Indication, Australia, 2016 - 2026 137
  • Chart 4 6: Synthetic Procedures by Indication, Australia, 2016 - 2026 140
  • Chart 4 7: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026 143
  • Chart 4 8: Orthopedic Growth Factor Procedures, Australia, 2016 - 2026 145
  • Chart 4 9: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Australia, 2016 - 2026 147
  • Chart 5 1: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026 151
  • Chart 5 2: Orthopedic Bone Graft Substitute Market Breakdown by Material, Australia, 2019 152
  • Chart 5 3: Orthopedic Bone Graft Substitute Market Breakdown by Material, Australia, 2026 153
  • Chart 5 4: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 157
  • Chart 5 5: Orthopedic Bone Graft Substitute Market Breakdown by Indication, Australia, 2019 158
  • Chart 5 6: Orthopedic Bone Graft Substitute Market Breakdown by Indication, Australia, 2026 159
  • Chart 5 7: Total Orthopedic Bone Graft Substitute Market, Australia, 2016 - 2026 161
  • Chart 5 8: Allograft Bone Graft Substitute Market, Australia, 2016 - 2026 163
  • Chart 5 9: Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 165
  • Chart 5 10: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, Australia, 2016 - 2026 179
  • Chart 5 11: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 181
  • Chart 5 12: Synthetic Bone Graft Substitute Market, Australia, 2016 - 2026 195
  • Chart 5 13: Synthetic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 197
  • Chart 5 14: Spine Bone Graft Substitute Market, Australia, 2016 - 2026 211
  • Chart 5 15: Cervical Spine Bone Graft Substitute Market, Australia, 2016 - 2026 213
  • Chart 5 16: Thoracolumbar Spine Bone Graft Substitute Market, Australia, 2016 - 2026 215
  • Chart 5 17: Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 217
  • Chart 5 18: Non-Union Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 219
  • Chart 5 19: Fresh Fracture Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 221
  • Chart 5 20: Large Joint Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 223
  • Chart 5 21: Hip Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 225
  • Chart 5 22: Knee Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 227
  • Chart 5 23: Foot Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 229
  • Chart 5 24: Craniomaxillofacial Bone Graft Substitute Market, Australia, 2016 - 2026 231
  • Chart 5 25: Oncology Bone Graft Substitute Market, Australia, 2016 - 2026 233
  • Chart 5 26: Leading Competitors, Orthopedic Bone Graft Substitute Market, Australia, 2019 239
  • Chart 6 1: Orthopedic Growth Factor Market, Australia, 2016 - 2026 243
  • Chart 6 2: Leading Competitors, Orthopedic Growth Factor Market, Australia, 2019 248
  • Chart 7 1: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026 254
  • Chart 7 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Australia, 2019 255
  • Chart 7 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Australia, 2026 256
  • Chart 7 4: Total Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 258
  • Chart 7 5: Single-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 260
  • Chart 7 6: Three-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 262
  • Chart 7 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Australia, 2019 267

LIST OF FIGURES

  • Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Australia, 2019 3
  • Figure 1 2: Companies Researched in this Report 4
  • Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Australia 5
  • Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Australia, 2016 - 2019 6
  • Figure 1 5: Orthopedic Biomaterials Procedures Covered, Australia 7
  • Figure 1 6: Orthopedic Biomaterials Markets Covered (1 of 2) 8
  • Figure 1 7: Orthopedic Biomaterials Markets Covered (2 of 2) 9
  • Figure 1 8: Key Report Updates 10
  • Figure 1 9: Version History 10
  • Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4) 28
  • Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4) 29
  • Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4) 30
  • Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4) 31
  • Figure 2 5: Growth Factor Products by Company 36
  • Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company 39
  • Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit 40
  • Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc 40
  • Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty 41
  • Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc 41
  • Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty 41
  • Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules 42
  • Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules 42
  • Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT 42
  • Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate) 43
  • Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease 44
  • Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites. 44
  • Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO. 45
  • Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System 45
  • Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation 46
  • Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction 46
  • Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy) 47
  • Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP) 47
  • Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™ 48
  • Figure 2 25: AttraX® Putty vs. Autograft in XLIF® 49
  • Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine 49
  • Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine 50
  • Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System 50
  • Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy 51
  • Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion 51
  • Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO) 52
  • Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material 52
  • Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal 53
  • Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® 53
  • Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation 54
  • Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2 54
  • Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody) 55
  • Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 55
  • Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation 56
  • Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment 56
  • Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA) 57
  • Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft 57
  • Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport 58
  • Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery 58
  • Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02) 59
  • Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK) 59
  • Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee 60
  • Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant 61
  • Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection 61
  • Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans 62
  • Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA) 62
  • Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401) 63
  • Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX) 63
  • Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA) 64
  • Figure 3 1: Currency Exchange Rate, 2019 67
  • Figure 3 2: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 (US$M) 69
  • Figure 3 3: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 (AU$M) 70
  • Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, Australia, 2016 - 2026 74
  • Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, Australia, 2019 77
  • Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, Australia, 2019 82
  • Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2) 104
  • Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2) 105
  • Figure 3 9: SWOT Analysis, Bioventus (1 of 2) 106
  • Figure 3 10: SWOT Analysis, Bioventus (2 of 2) 107
  • Figure 3 11: SWOT Analysis, DePuy Synthes 108
  • Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals 109
  • Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals 110
  • Figure 3 14: SWOT Analysis, Genzyme (Sanofi) 111
  • Figure 3 15: SWOT Analysis, Harvest Technologies 112
  • Figure 3 16: SWOT Analysis, Integra LifeSciences 113
  • Figure 3 17: SWOT Analysis, Medtronic 114
  • Figure 3 18: SWOT Analysis, MTF 115
  • Figure 3 19: SWOT Analysis, NuVasive 116
  • Figure 3 20: SWOT Analysis, Orthofix 117
  • Figure 3 21: SWOT Analysis, RTI Surgical 118
  • Figure 3 22: SWOT Analysis, Stryker 119
  • Figure 3 23: SWOT Analysis, Vericel Corporation 120
  • Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2) 121
  • Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2) 122
  • Figure 4 1: Orthopedic Biomaterials Procedures by Segment, Australia, 2016 - 2026 124
  • Figure 4 2: Units per Procedure by Indication, Bone Graft Substitute Market, Australia, 2016- 2026 126
  • Figure 4 3: Orthopedic Bone Grafting Procedures by Material, Australia, 2016 - 2026 127
  • Figure 4 4: Autograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2) 129
  • Figure 4 5: Autograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2) 130
  • Figure 4 6: Allograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2) 132
  • Figure 4 7: Allograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2) 133
  • Figure 4 8: DBM Allograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2) 135
  • Figure 4 9: DBM Allograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2) 136
  • Figure 4 10: Synthetic Procedures by Indication, Australia, 2016 - 2026 (1 of 2) 138
  • Figure 4 11: Synthetic Procedures by Indication, Australia, 2016 - 2026 (2 of 2) 139
  • Figure 4 12: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026 (1 of 2) 141
  • Figure 4 13: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026 (2 of 2) 142
  • Figure 4 14: Orthopedic Growth Factor Procedures, Australia, 2016 - 2026 144
  • Figure 4 15: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Australia, 2016 - 2026 146
  • Figure 5 1: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026 (US$M) 149
  • Figure 5 2: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026 (AU$M) 150
  • Figure 5 3: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M) 155
  • Figure 5 4: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (AU$M) 156
  • Figure 5 5: Total Orthopedic Bone Graft Substitute Market, Australia, 2016 - 2026 160
  • Figure 5 6: Allograft Bone Graft Substitute Market, Australia, 2016 - 2026 162
  • Figure 5 7: Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M) 164
  • Figure 5 8: Spine Allograft Market, Australia, 2016 - 2026 166
  • Figure 5 9: Cervical Spine Allograft Market, Australia, 2016 - 2026 167
  • Figure 5 10: Thoracolumbar Spine Allograft Market, Australia, 2016 - 2026 168
  • Figure 5 11: Trauma Allograft Market, Australia, 2016 - 2026 169
  • Figure 5 12: Non-Union Trauma Allograft Market, Australia, 2016 - 2026 170
  • Figure 5 13: Fresh Fracture Trauma Allograft Market, Australia, 2016 - 2026 171
  • Figure 5 14: Large Joint Reconstruction Allograft Market, Australia, 2016 - 2026 172
  • Figure 5 15: Hip Reconstruction Allograft Market, Australia, 2016 - 2026 173
  • Figure 5 16: Knee Reconstruction Allograft Market, Australia, 2016 - 2026 174
  • Figure 5 17: Foot Reconstruction Allograft Market, Australia, 2016 - 2026 175
  • Figure 5 18: Craniomaxillofacial Allograft Market, Australia, 2016 - 2026 176
  • Figure 5 19: Oncology Allograft Market, Australia, 2016 - 2026 177
  • Figure 5 20: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, Australia, 2016 - 2026 178
  • Figure 5 21: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M) 180
  • Figure 5 22: Spine DBM Allograft Market, Australia, 2016 - 2026 182
  • Figure 5 23: Cervical Spine DBM Allograft Market, Australia, 2016 - 2026 183
  • Figure 5 24: Thoracolumbar Spine DBM Allograft Market, Australia, 2016 - 2026 184
  • Figure 5 25: Trauma DBM Allograft Market, Australia, 2016 - 2026 185
  • Figure 5 26: Non-Union Trauma DBM Allograft Market, Australia, 2016 - 2026 186
  • Figure 5 27: Fresh Fracture Trauma DBM Allograft Market, Australia, 2016 - 2026 187
  • Figure 5 28: Large Joint Reconstruction DBM Allograft Market, Australia, 2016 - 2026 188
  • Figure 5 29: Hip Reconstruction DBM Allograft Market, Australia, 2016 - 2026 189
  • Figure 5 30: Knee Reconstruction DBM Allograft Market, Australia, 2016 - 2026 190
  • Figure 5 31: Foot Reconstruction DBM Allograft Market, Australia, 2016 - 2026 191
  • Figure 5 32: Craniomaxillofacial DBM Allograft Market, Australia, 2016 - 2026 192
  • Figure 5 33: Oncology DBM Allograft Market, Australia, 2016 - 2026 193
  • Figure 5 34: Synthetic Bone Graft Substitute Market, Australia, 2016 - 2026 194
  • Figure 5 35: Synthetic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M) 196
  • Figure 5 36: Spine Synthetic Market, Australia, 2016 - 2026 198
  • Figure 5 37: Cervical Spine Synthetic Market, Australia, 2016 - 2026 199
  • Figure 5 38: Thoracolumbar Spine Synthetic Market, Australia, 2016 - 2026 200
  • Figure 5 39: Trauma Synthetic Market, Australia, 2016 - 2026 201
  • Figure 5 40: Non-Union Trauma Synthetic Market, Australia, 2016 - 2026 202
  • Figure 5 41: Fresh Fracture Trauma Synthetic Market, Australia, 2016 - 2026 203
  • Figure 5 42: Large Joint Reconstruction Synthetic Market, Australia, 2016 - 2026 204
  • Figure 5 43: Hip Reconstruction Synthetic Market, Australia, 2016 - 2026 205
  • Figure 5 44: Knee Reconstruction Synthetic Market, Australia, 2016 - 2026 206
  • Figure 5 45: Foot Reconstruction Synthetic Market, Australia, 2016 - 2026 207
  • Figure 5 46: Craniomaxillofacial Synthetic Market, Australia, 2016 - 2026 208
  • Figure 5 47: Oncology Synthetic Market, Australia, 2016 - 2026 209
  • Figure 5 48: Spine Bone Graft Substitute Market, Australia, 2016 - 2026 210
  • Figure 5 49: Cervical Spine Bone Graft Substitute Market, Australia, 2016 - 2026 212
  • Figure 5 50: Thoracolumbar Spine Bone Graft Substitute Market, Australia, 2016 - 2026 214
  • Figure 5 51: Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 216
  • Figure 5 52: Non-Union Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 218
  • Figure 5 53: Fresh Fracture Trauma Bone Graft Substitute Market, Australia, 2016 - 2026 220
  • Figure 5 54: Large Joint Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 222
  • Figure 5 55: Hip Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 224
  • Figure 5 56: Knee Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 226
  • Figure 5 57: Foot Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026 228
  • Figure 5 58: Craniomaxillofacial Bone Graft Substitute Market, Australia, 2016 - 2026 230
  • Figure 5 59: Oncology Bone Graft Substitute Market, Australia, 2016 - 2026 232
  • Figure 5 60: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, Australia, 2019 235
  • Figure 5 61: Leading Competitors, Orthopedic Bone Graft Substitute Market, Australia, 2019 238
  • Figure 6 1: Orthopedic Growth Factor Market, Australia, 2016 - 2026 242
  • Figure 6 2: Drivers and Limiters, Orthopedic Growth Factor Market, Australia, 2019 245
  • Figure 6 3: Leading Competitors, Orthopedic Growth Factor Market, Australia, 2019 247
  • Figure 7 1: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026 (US$M) 252
  • Figure 7 2: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026 (AU$M) 253
  • Figure 7 3: Total Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 257
  • Figure 7 4: Single-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 259
  • Figure 7 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026 261
  • Figure 7 6: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Australia, 2019 264
  • Figure 7 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Australia, 2019 266
Back to Top